- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Solid Performers
U.S. Pharmaceuticals & Biotech Undervalued Solid Performers
Results
4
Companies meeting several financial criteria and filtered from the entire market.
4 companies
United Therapeutics
Market Cap: US$24.8b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$564.81
7D
8.0%
1Y
93.1%
Neurocrine Biosciences
Market Cap: US$13.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$131.60
7D
2.6%
1Y
37.6%
ICON
Market Cap: US$8.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR
US$114.19
7D
11.9%
1Y
-25.7%
Zai Lab
Market Cap: US$2.3b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$20.41
7D
13.4%
1Y
-35.8%